NYMC Faculty Publications
A Review of AbobotulinumtoxinA (Dysport)
Author Type(s)
Faculty
DOI
10.1177/1090820X12474632
Journal Title
Aesthetic Surgery Journal
First Page
13
Last Page
13
Document Type
Article
Publication Date
3-1-2013
Department
Otolaryngology
Abstract
AbobotulinumtoxinA was approved by the US Food and Drug Administration in 2009 as the second botulinum neurotoxin type A (BoNTA) for use in facial aesthetics. This article provides an overview of abobotulinumtoxinA's applications and indications as well as safety and efficacy data. AbobotulinumtoxinA is generally well tolerated. Adverse events from abobotulinumtoxinA are similar to those reported with other BoNTA products. Clinical applications of the product are also discussed in this article. Information on handling, storage, and dosing is provided.
Recommended Citation
Lorenc, Z., Kenkel, J., Fagien, S., Hirmand, H., Nestor, M., Sclafani, A., Sykes, J., & Waldorf, H. (2013). A Review of AbobotulinumtoxinA (Dysport). Aesthetic Surgery Journal, 33 (1 Suppl), 13-13. https://doi.org/10.1177/1090820X12474632
